Citations

Clear

50 citation(s) found for "Gilbert, Mark R".

Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop
Peñas-Prado, Marta , Theeler, Brett , Cordeiro, Brittany, Mahajan, Anita , Willmarth, Nicole E. , Aldape, Kenneth, Gajjar, Amar , Kelly, William , Rao, Ganesh , Raygada, Margarita , Siegel, Christine, Romo, Carlos G. , Workshop, NCI-CONNECT Adult Medulloblastoma, Camphausen, Kevin , Cordeiro, Brittany, Galanis, E., Wall, Kathleen, Abdullaev, Zied , Aldape, Kenneth, Chapman, Lesley M. , Leach, Danielle, Acquaye, Alvina , Gonzalez, Javier , Majd, Nazanin , Oliver, Kathy , Tsien, Christina , Wen, Patrick Y. , Armstrong, Terri S , Romo, Carlos , Dunkel, Ira J. , Hau, Peter , Robinson, Giles , Aboud, Orwa , Butman, John A. , Armstrong, Terri S. , Gilbert, Mark R. , Workshop, NCI-CONNECT Adult Medulloblastoma, Cordeiro, Brittany, Aldape, Kenneth, Celiku, Orieta , Forsyth, Peter A , Jung, Jinkyu , Nair, Nishanth Ulhas , Schischlik, Fiorella , Shih, Helen A. , Wu, Jing , Leeper, Heather , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology Advances | August 17, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaa097 | PMID 33005896 Get It

AbstractBackgroundMedulloblastoma (MB) is a rare brain tumor occurring more frequently in children in whom research has been primarily focused. Treatment recommendations in adults are mainly based on retrospective data and pediatric experience; however, molecular features and treatment tolerance differ between the 2 age groups. In adults, prognostic tools are suboptimal, late recurrences are typical, and long-term sequelae remain understudied. Treatment has not adapted to molecular classification advances; thus, the survival rate of adult MB has not improved.MethodsIn 2017, the National Cancer Institute (NCI) received support from the Cancer Moonshot℠ to address the challenges and unmet needs of adults with rare central nervous system tumors through NCI-CONNECT, a program that creates partnerships among patients, health care professionals, researchers, and advocacy organizations. On November 25, 2019, NCI-CONNECT convened leading clinicians and scientists in a workshop to review advances in research, share scientific insights, and discuss clinical challenges in adult MB.ResultsWorking groups identified unmet needs in clinical trial design, tissue acquisition and testing, tumor modeling, and measurement of clinical outcomes.ConclusionsParticipants identified opportunities for collaboration; discussed plans to create a working group of clinicians, researchers, and patient advocates; and developed specific action items to expedite progress in adult MB.
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
Bell, Erica H. , Shaw, Edward G. , Buckner, Jan C. , Barger, Geoffrey, Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , McElroy, Joseph P., Fleming, Jessica L. , Timmers, Cynthia , Salavaggione, Andrea L., Aldape, Kenneth , Brachman, David, Gertler, Stanley Z., Murtha, Albert , Schultz, Christopher J. , Hunter, G.K., Crocker, Ian , Won, Minhee , Chakravarti, Arnab , Chakravarti, Arnab , Chakravarti, Arnab , Zhang, Jianwen , Mehta, Minesh P. , Gilbert, Mark R. , Becker, Aline Paixão , Liu, Ziyan , Johnson, David, Laack, Nadia N.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2020 | Volume: 38 | Issue: 29 | Pages: 3407-3417

10.1200/jco.19.02983 | PMID 32706640 Get It

PURPOSENRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375 ) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802.METHODSIDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates.RESULTSOf the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH-wild type, 43 (41%) were IDH-mutant/non-codeleted, and 37(35%) were IDH-mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH-mutant/non-codeleted and IDH-mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH-wild-type subgroup.CONCLUSIONThis study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH-mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas
Boxerman, Jerrold L. , Quarles, C. Chad , Hu, Leland , Gerstner, Elizabeth R. , Smits, Marion , Barboriak, Daniel P. , Huang, Raymond, Wick, Wolfgang , Weller, Michael , Kalpathy–Cramer, Jayashree , Shankar, Lalitha , Jacobs, Paula , Chung, Caroline , Bent, Martin J. van den , Chang, Susan M. , Yung, Wai Kuen, Wen, Patrick Y. , Rosen, Bruce R. , Arons, David F., Kingston, Ann E, Sandak, David, Wallace, M. Z., Musella, Al , Haynes, Chas, Weller, Michael , van den Bent, Martin J , Boxerman, Jerrold L , Wick, Wolfgang , Smits, Marion , Barboriak, Daniel P , Erickson, Bradley J. , Kaufmann, Timothy J. , Galanis, Evanthia , Chang, Susan Marina , Yung, W K Al, Cloughesy, Timothy F. , Wen, Patrick Yung , Gilbert, Mark R. , Ellingson, Benjamin M. , Schmainda, Kathleen M

Mayo Clinic

Neuro-Oncology | June 3, 2020 | Volume: 22 | Issue: 9 | Pages: 1262-1275

10.1093/neuonc/noaa141 | PMID 32516388 Get It

Abstract Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with the standardized brain tumor imaging protocol (BTIP) for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this paper provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40–50 ms at 1.5 T, 20–35 ms at 3 T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Weller, Michael , Lee, Eudocia Q. , Barnholtz‐Sloan, Jill S. , Barthel, Floris P , Batchelor, Tracy T. , Chang, Susan M. , DeGroot, John, Hegi, Monika E. , Huang, Raymond Y. , Lassman, Andrew B. , Lim, Michael , Mellinghoff, Ingo K. , Minniti, Giuseppe , Nathanson, David A. , Platten, Michael , Preusser, Matthias , Roth, Patrick , Sanson, Marc , Schiff, David , Short, Susan , Taphoorn, Martin , Tonn, Joerg-Christian, Tsang, Jonathan , Verhaak, Roel G.W. , Deimling, Andreas von , Zadeh, Gelareh , Reardon, David A. , Aldape, Kenneth , Bent, Martin J. van den , Weller, Michael , Short, Susan C , van den Bent, Martin J , Barnholtz-Sloan, Jill S , Platten, Michael , Preusser, Matthias , Sanson, Marc , von Deimling, Andreas , Mellinghoff, Ingo K , Huang, Raymond , Roth, Patrick , Barthel, Floris P , Wen, Patrick Yung , Alexander, Brian M. , Bindra, Ranjit S. , Chiocca, E Antonio , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Horbinski, Craig , Rhun, Émilie Le , Mehta, Minesh P. , Tonn, Joerg-Christian , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | April 20, 2020 | Volume: 22 | Issue: 8 | Pages: 1073-1113

10.1093/neuonc/noaa106 | PMID 32328653 Get It

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).
Won, Minhee , Blumenthal, Deborah T. , Vogelbaum, Michael A. , Colman, Howard , Jenkins, Robert B. , Brown, Paul D. , Jaeckle, Kurt A. , Schiff, David , Dignam, James J., Atkins, James N., Brachman, David, Werner‐Wasik, Maria, Komaki, Ritsuko , Aldape, Kenneth , Sulman, Erik P. , Colman, Howard , Chakravarti, Arnab , Jeraj, Robert , Gilbert, Mark R. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: LBA2010-LBA2010

10.1200/jco.2013.31.15_suppl.lba2010 Get It

LBA2010 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
Dignam, James J., Won, Minhee , Blumenthal, Deborah T. , Vogelbaum, Michael A. , Aldape, Kenneth , Colman, Howard , Brown, Paul D. , Jaeckle, Kurt A. , Schiff, David , Atkins, James N., Brachman, David, Werner‐Wasik, Maria, Komaki, Ritsuko , Gilbert, Mark R. , Colman, Howard , Chakravarti, Arnab , Jeraj, Robert , Armstrong, Terri S. , Wefel, Jeffrey S. , Sulman, Erik P. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 1-1

10.1200/jco.2013.31.15_suppl.1 Get It

1 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Sunday, June, 2, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Brown, Paul D. , Gondi, Vinai , Pugh, Stephanie L. , Tomé, Wolfgang A. , Bovi, Joseph , Robinson, Clifford G. , Konski, André , Khuntia, Deepak , Grosshans, David R. , Benzinger, Tammie L.S. , Devisetty, Kiran , Shah, Sunjay, Usuki, Kenneth Y., Anderson, Bethany , Yoon, Harold, Li, Jing , Chmura, Steven J. , Shi, Wenyin , Deshmukh, Snehal, Kachnic, Lisa A. , Oncology, for NRG, Robinson, Clifford , Benzinger, Tammie L S , Shi, Wenyin , Wefel, Jeffrey S. , Armstrong, Terri S. , Bruner, Deborah Watkins , Gilbert, Mark R. , Roberge, David , Kundapur, Vijayananda , Stea, Baldassarre , Laack, Nadia N. , Kruser, Tim J. , Mehta, Minesh P. , Oncology, for NRG

Mayo Clinic

Journal of Clinical Oncology | February 14, 2020 | Volume: 38 | Issue: 10 | Pages: 1019-1029

10.1200/jco.19.02767 | PMID 32058845 Get It

PURPOSE Radiation dose to the neuroregenerative zone of the hippocampus has been found to be associated with cognitive toxicity. Hippocampal avoidance (HA) using intensity-modulated radiotherapy during whole-brain radiotherapy (WBRT) is hypothesized to preserve cognition. METHODS This phase III trial enrolled adult patients with brain metastases to HA-WBRT plus memantine or WBRT plus memantine. The primary end point was time to cognitive function failure, defined as decline using the reliable change index on at least one of the cognitive tests. Secondary end points included overall survival (OS), intracranial progression-free survival (PFS), toxicity, and patient-reported symptom burden. RESULTS Between July 2015 and March 2018, 518 patients were randomly assigned. Median follow-up for alive patients was 7.9 months. Risk of cognitive failure was significantly lower after HA-WBRT plus memantine versus WBRT plus memantine (adjusted hazard ratio, 0.74; 95% CI, 0.58 to 0.95; P = .02). This difference was attributable to less deterioration in executive function at 4 months (23.3% v 40.4%; P = .01) and learning and memory at 6 months (11.5% v 24.7% [ P = .049] and 16.4% v 33.3% [ P = .02], respectively). Treatment arms did not differ significantly in OS, intracranial PFS, or toxicity. At 6 months, using all data, patients who received HA-WBRT plus memantine reported less fatigue ( P = .04), less difficulty with remembering things ( P = .01), and less difficulty with speaking ( P = .049) and using imputed data, less interference of neurologic symptoms in daily activities ( P = .008) and fewer cognitive symptoms ( P = .01). CONCLUSION HA-WBRT plus memantine better preserves cognitive function and patient-reported symptoms, with no difference in intracranial PFS and OS, and should be considered a standard of care for patients with good performance status who plan to receive WBRT for brain metastases with no metastases in the HA region.
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients
Lee, Eudocia Q. , Weller, Michael , Sul, Joohee, Bagley, Stephen , Sahebjam, Solmaz , Bent, Martin J. van den , Ahluwalia, Manmeet S. , Campian, Jian , Holdhoff, Matthias , Lesser, Glenn J. , Lieberman, Frank S. , Peñas-Prado, Marta , Schreck, Karisa C. , Vogelbaum, Michael A. , Walbert, Tobias , Chang, Susan M. , Reardon, David A. , Wen, Patrick Y. , Weller, Michael , van den Bent, Martin J , Ahluwalia, Manmeet S , Galanis, Evanthia , Gilbert, Mark R. , Mehta, Minesh P. , Strowd, Roy E. , Chang, Susan Marina , Nabors, Burt , Grossman, Stuart A. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | January 23, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noaa015 | PMID 31974566 Get It

AbstractBuilding on an initiative to enhance clinical trial participation involving the Society for Neuro-Oncology, the Response Assessment in Neuro-Oncology Working Group, patient advocacy groups, clinical trial cooperative groups, and other partners, we evaluate the impact of eligibility criteria and trial conduct on neuro-oncology clinical trial participation. Clinical trials often carry forward eligibility criteria from prior studies that may be overly restrictive and unnecessary and needlessly limit patient accrual. Inclusion and exclusion criteria should be evaluated based on the goals and design of the study and whether they impact patient safety and/or treatment efficacy. In addition, we evaluate clinical trial conduct as a barrier to accrual and discuss strategies to minimize such barriers for neuro-oncology trials.
RTHP-18. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR NEWLY DIAGNOSED GBM: SECONDARY ANALYSIS COMPARISON OF GENDER AND NEUTROPHIL-LYMPHOCYTE RATIO (NLR) IN GBM OUTCOMES
Randall, James W. , Grosshans, David R. , Dibaj, Seyedeh, Milton, D., McAvoy, Sarah , McGovern, Susan L. , McAleer, Mary Frances , Ghia, Amol J. , Sulman, Erik P. , Peñas-Prado, Marta , DeGroot, John, Heimberger, Amy B. , Mahajan, Anita , Brown, Paul D. , Sulman, Erik P , Feghali, Karine A. Al , Wefel, Jeffrey S. , Li, Jing , Paulino, Arnold C. , Wang, Jihong , Heimberger, Amy B. , Armstrong, Terri S. , Gilbert, Mark R. , Chung, Caroline

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi213-vi213

10.1093/neuonc/noz175.889 Get It

Abstract BACKGROUND While glioblastoma (GBM) is more prevalent in males, studies show that females with GBM tend to have longer overall survival (OS) than males. Pretreatment neutrophil to lymphocyte ratio (NLR) has also proven to be prognostic in GBM, with lower NLR having favorable outcomes. This secondary analysis of a prospective randomized trial of proton vs. photon intensity modulated radiotherapy aims to explore the interaction of gender and NLR on GBM outcomes. METHODS Analysis was performed on the full patient population. Kaplan-Meier methods estimated OS with censoring at last follow-up for those who were alive. Univariate (UVA) and multivariate (MVA)Cox proportional hazards models assessed predictors of OS. RESULTS Of 90 patients, 77 were included (43 males; 34 females) with median age of 52 years (range: 26–82 years). Median OS was longer for females than males (30.7 vs 18.2 months, p=0.004). On UVA, patients with NLR below median value (NLR= 3.1) tended to have longer OS than those above median, though not meeting statistical significance (23.1 vs. 17.9 months, p=0.051). Difference in OS was statistically significant in females (OS 36.4 months NLR >median vs. 16.7 months NLR< median, p=0.002), but not in males (OS 17.8 months NLR >median vs. 19.1 NLR< median, p=0.95). MVA analysis was consistent, with female gender predicting reduced hazard ratio (HR) (0.28, p=0.034) and females with below median NLR showing a reduced HR over those with above median (0.28, p=0.005). Again, males did not benefit (HR 0.90, p=0.77). CONCLUSION Consistent with prior publications, females and all patients with lower pre-treatment NLR with newly diagnosed GBM had longer OS. However, combining these two factors revealed that the benefits from lower pre-treatment NLR were conferred only in females with no impact on males. This different impact of NLR between genders may suggest innate immune differences in gender during response to malignancy.
NIMG-03. PROSPECTIVE PHASE II RANDOMIZED TRIAL COMPARING PROTON THERAPY VS. PHOTON IMRT FOR GBM: SECONDARY ANALYSIS COMPARISON OF PROGRESSION FREE SURVIVAL BETWEEN RANO VS. CLINICAL AND RADIOLOGICAL ASSESSMENT
Randall, James W. , Grosshans, David R. , Dibaj, Seyedeh, McAvoy, Sarah , McGovern, Susan L. , McAleer, M.F., Ghia, Amol J. , Sulman, Erik P. , Peñas-Prado, Marta , DeGroot, John, Heimberger, Amy B. , Mahajan, Anita , Brown, Paul D. , Sulman, Erik P , Feghali, Karine A. Al , Wefel, Jeffrey S. , Guha‐Thakurta, Nandita , Li, Jing , Paulino, Arnold C. , Wang, Jihong , Heimberger, Amy B. , Armstrong, Terri S. , Gilbert, Mark R. , Chung, Caroline

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi161-vi162

10.1093/neuonc/noz175.675 Get It

Abstract PURPOSE To compare tumor progression based on clinical radiological assessment and on Response Assessment in Neuro-Oncology (RANO) criteria between GBM patients treated with proton radiotherapy (PT) vs. photon intensity modulated radiotherapy (IMRT). METHODS Eligible patients were enrolled on the described prospective phase II trial and had MR imaging at baseline and follow-up beyond 12 weeks from treatment completion. ‘Clinical’ progression was based on a radiology report of progression in combination with changes in treatment due to suspected disease progression. A single blinded observer applied RANO criteria to determine the RANO-based tumor progression. RESULTS Of 90 enrolled patients, 66 were evaluable, with median follow-up of 19.8 (Range: 3.2–65.1) months; median of 22.6 months for PT (n=25) vs. 18.9 months for IMRT (n=41). Median time to progression (TTP) was 7.9 months based on clinical progression criteria (8.1 months IMRT, 6.3 months PT) and 7.2 months (7.3 months IMRT, 5.7 months PT) by RANO criteria (p=ns for all). Median ‘clinical’ progression-free survival (PFS) was 8.7 (Range: 6.4–11.1) months; 8.9 months IMRT vs. 8.7 months PT (p=0.065). Median RANO PFS was 8.3 (range, 5.8–11.6) months: 8.3 months IMRT vs. 6.9 months PT (p=0.226). There were 14 discrepant cases: 3 had progression based on ‘clinical’ but not RANO criteria, and 11 had progression based on RANO but not ‘clinical’ criteria. CONCLUSION Based on this secondary analysis of a randomized trial of PT vs. IMRT for GBM, there was no difference in tumor progression relative to treatment technique used. There was no statistical difference in PFS noted between clinical and RANO-based assessments, but RANO criteria identified progression more often than clinical assessment, and TTP was shortened with the use of RANO criteria alone. Further development of tumor assessment tools that improve consistency and accuracy of determining tumor progression are needed to guide therapeutic trials in GBM.